Combination chelation therapy.
deferasirox
deferiprone
deferoxamine
iron chelation
iron overload
thalassemia
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
medline:
16
11
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Combination chelation therapies are considered in transfusion-dependent thalassemia patients for whom monotherapy regimens have failed to achieve iron balance or intensification of iron chelation therapy is required for the rapid reduction of excess iron to avoid permanent organ damage. Combination chelation may provide a more flexible approach for individualizing chelation therapy, thereby improving tolerability, adherence, and quality of life. In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days. Clinical studies have established the safety and efficacy of chelation combinations. However, real-life data with combination therapies indicate the significance of compliance for a meaningful reduction in iron overload compared to monotherapies.
Substances chimiques
Deferasirox
V8G4MOF2V9
Deferoxamine
J06Y7MXW4D
Deferiprone
2BTY8KH53L
Benzoates
0
Triazoles
0
Pyridones
0
Iron Chelating Agents
0
Iron
E1UOL152H7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-41Informations de copyright
© 2023 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals LLC on behalf of The New York Academy of Sciences.
Références
Porter, J. B., & Shah, F. T. (2010). Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematology Oncology Clinics of North America, 24(6), 1109-1130. https://doi.org/10.1016/j.hoc.2010.08.015
Porter, J. B., Evangeli, M., & El-Beshlawy, A. (2011). The challenges of adherence and persistence with iron chelation therapy. International Journal of Hematology, 94(5), 453-460. https://doi.org/10.1007/s12185-011-0927-3
Galanello, R., Agus, A., Campus, S., Danjou, F., Giardina, P. J., & Grady, R. W. (2010). Combined iron chelation therapy. Annals of the New York Academy of Sciences, 1202, 79-86. https://doi.org/10.1111/j.1749-6632.2010.05591.x
Cabantchik, Z., Breuer, W., Zanninelli, G., & Cianciulli, P. (2005). LPI-labile plasma iron in iron overload. Best Practice & Research, Clinical Haematology, 18(2), 277-287. https://doi.org/10.1016/j.beha.2004.10.003
Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., & Cabantchik, Z. I. (2003). Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood, 102(7), 2670-2677. https://doi.org/10.1182/blood-2003-03-0807
Otto-Duessel, M., Aguilar, M., Nick, H., Moats, R., & Wood, J. C. (2007). Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Experimental Hematology, 35(7), 1069-1073. https://doi.org/10.1016/j.exphem.2007.04.001
Jensen, P. D., Jensen, F. T., Christensen, T., Eiskjaer, H., Baandrup, U., & Nielsen, J. L. (2003). Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool. Blood, 101(11), 4632-4639. https://doi.org/10.1182/blood-2002-09-2754
Di Tucci, A. A., Matta, G., Deplano, S., Gabbas, A., Depau, C., Derudas, D., Caocci, G., Agus, A., & Angelucci, E. (2008). Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica, 93(9), 1385-1388. https://doi.org/10.3324/haematol.12759
De Domenico, I., Mcvey Ward, D., & Kaplan, J. (2009). Specific iron chelators determine the route of ferritin degradation. Blood, 114(20), 4546-4551. https://doi.org/10.1182/blood-2009
Waldmeier, F., Bruin, G. J., Glaenzel, U., Hazell, K., Sechaud, R., Warrington, S., & Porter, J. B. (2010). Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metabolism and Disposition, 38(5), 808-816. https://doi.org/10.1124/dmd.109.030833
Hoffbrand, A. V., Cohen, A., & Hershko, C. (2003). Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 102(1), 17-24. https://doi.org/10.1182/blood-2002-06-1867
Noetzli, L. J., Carson, S. M., Nord, A. S., Coates, T. D., & Wood, J. C. (2008). Longitudinal analysis of heart and liver iron in thalassemia major. Blood, 112(7), 2973-2978. https://doi.org/10.1182/blood-2008-04-148767
Zanninelli, G., Breuer, W., & Cabantchik, Z. I. (2009). Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. British Journal of Haematology, 147(5), 744-751. https://doi.org/10.1111/j.1365-2141.2009.07907.x
Cabantchik, Z. I. (2014). Labile iron in cells and body fluids: Physiology, pathology, and pharmacology. Frontiers in Pharmacology, 5, 45. https://doi.org/10.3389/fphar.2014.00045
Glickstein, H., Ben El, R., Shvartsman, M., & Cabantchik, Z. I. (2005). Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells. Blood, 106(9), 3242-3250. https://doi.org/10.1182/blood-2005-02-0460
Glickstein, H., El, R. B., Link, G., Breuer, W., Konijn, A. M., Hershko, C., Nick, H., & Cabantchik, Z. I. (2006). Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood, 108(9), 3195-3203. https://doi.org/10.1182/blood-2006-05-020867
Pennell, D. J. (2006). Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107(9), 3738-3744. https://doi.org/10.1182/blood-2005-07-2948
Pennell, D. J., Porter, J. B., Piga, A., Lai, Y., El-Beshlawy, A., Belhoul, K. M., Elalfy, M., Yesilipek, A., Kilinç, Y., Lawniczek, T., Habr, D., Weisskopf, M., Zhang, Y., & Aydinok, Y. (2014). A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood, 123(10), 1447-1454. https://doi.org/10.1182/blood-2013-04-497842
Anderson, L. J., Westwood, M. A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J. B., Malcolm Walker, J., & Pennell, D. J. (2004). Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 127(3), 348-355. https://doi.org/10.1111/j.1365-2141.2004.05202.x
Davis, B. A., & Porter, J. B. (2000). Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk-thalassemia. Blood, 95(4), 1229-1236.
Wonke, B., Wright, C., & Hoffbrand, A. V. (1998). Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology, 103(2), 361-364. https://doi.org/10.1046/j.1365-2141.1998.01002
Giardina, P. J., & Grady, R. W. (2001). Chelation therapy in beta-thalassemia: An optimistic update. Seminars in Hematology, 38(4), 360-366. https://doi.org/10.1016/s0037-1963(01)90030-7
Breuer, W., Ermers, M. J. J., Pootrakul, P., Abramov, A., Hershko, C., & Cabantchik, Z. I. (2001). Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood, 97(3), 792-798.
Evans, P., Kayyali, R., Hider, R. C., Eccleston, J., & Porter, J. B. (2010). Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Translational Research, 156(2), 55-67. https://doi.org/10.1016/j.trsl.2010.05.002
Link, G., Konijn, A. M., Breuer, W., Cabantchik, Z. I., & Hershko, C. (2001). Exploring the “iron shuttle” hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. Journal of Laboratory and Clinical Medicine, 138(2), 130-138. https://doi.org/10.1067/mlc.2001.116487
Aydinok, Y., Ulger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., Zimmermann, A., & Manz, C. (2007). A randomized controlled 1-year study of daily deferiprone plus twice weekly desferoxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica, 92(12), 1599-1606. https://doi.org/10.3324/haematol.11414
Tanner, M. A., Galanello, R., Dessi, C., Smith, G. C., Westwood, M. A., Agus, A., Roughton, M., Assomull, R., Nair, S. V., Walker, J. M., & Pennell, D. J. (2007). A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115(14), 1876-1884. https://doi.org/10.1161/CIRCULATIONAHA.106.648790
Porter, J. B., Wood, J., Olivieri, N., Vichinsky, E. P., Taher, A., Neufeld, E., Giardina, P., Thompson, A., Moore, B., Evans, P., Kim, H.-Y., Macklin, E. A., & Trachtenberg, F. (2013). Treatment of heart failure in adults with thalassemia major: Response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 15(1), 38. https://doi.org/10.1186/1532-429X-15-38
Cappellini, M. D. (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 107(9), 3455-3462. https://doi.org/10.1182/blood-2005-08-3430
Taher, A., El-Beshlawy, A., Elalfy, M. S., Al Zir, K., Daar, S., Habr, D., Kriemler-Krahn, U., Hmissi, A., & Al Jefri, A. (2009). Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study. European Journal of Haematology, 82(6), 458-465. https://doi.org/10.1111/j.1600-0609.2009.01228.x
Pennell, D. J., Porter, J. B., Cappellini, M. D., El-Beshlawy, A., Chan, L. L., Aydinok, Y., Elalfy, M. S., Sutcharitchan, P., Li, C.-K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., & Taher, A. (2010). Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood, 115(12), 2364-2371. https://doi.org/10.1182/blood-2009-04-217455
Cappellini, M. D., Bejaoui, M., Agaoglu, L., Canatan, D., Capra, M., Cohen, A., Drelichman, G., Economou, M., Fattoum, S., Kattamis, A., Kilinc, Y., Perrotta, S., Piga, A., Porter, J. B., Griffel, L., Dong, V., Clark, J., & Aydinok, Y. (2011). Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years’ follow-up. Blood, 118(4), 884-893. https://doi.org/10.1182/blood-2010-11-316646
Aydinok, Y. (2018). Iron chelation therapy as a modality of management. Hematology Oncology Clinics of North America, 32(2), 261-275. https://doi.org/10.1016/j.hoc.2017.12.002
Neufeld, E. J. (2006). Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood, 107(9), 3436-3441. https://doi.org/10.1182/blood-2006-02-002394
Chirnomas, D., Smith, A. L., Braunstein, J., Finkelstein, Y., Pereira, L., Bergmann, A. K., Grant, F. D., Paley, C., Shannon, M., & Neufeld, E. J. (2009). Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood, 114(19), 4009-4013. https://doi.org/10.1182/blood-2009-05-222729
Kattamis, A., Aydinok, Y., & Taher, A. (2018). Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. European Journal of Haematology, 101(3), 272-282. https://doi.org/10.1111/ejh.13111
Lu, M.-Y., Wang, N., Wu, W.-H., Lai, C.-W., Kuo, P.-H., Chiang, P.-H., Lin, K.-H., & Wu, T.-H. (2015). Simultaneous determination of plasma deferasirox and deferasirox-iron complex using an HPLC-UV system and pharmacokinetics of deferasirox in patients with β-thalassemia major: Once-daily versus twice-daily administration. Clinical Therapeutics, 37(8), 1751-1760. https://doi.org/10.1016/j.clinthera.2015.05.506
Hershko, C., Konijn, A. M., Nick, H. P., Breuer, W., Cabantchik, Z. I., & Link, G. (2001). ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood, 97(4), 1115-1122. https://doi.org/10.1182/blood.v97.4.1115
Otto-Duessel, M., Brewer, C., Gonzalez, I., Nick, H., & Wood, J. C. (2008). Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematologica, 120(2), 123-128. https://doi.org/10.1159/000174757
Grady, R. W., Galanello, R., Randolph, R. E., Kleinert, D. A., Dessi, C., & Giardina, P. J. (2013). Toward optimizing the use of deferasirox: Potential benefits of combined use with deferoxamine. Haematologica, 98(1), 129-135. https://doi.org/10.3324/haematol.2012.070607
Vlachodimitropoulou Koumoutsea, E., Garbowski, M., & Porter, J. (2015). Synergistic intracellular iron chelation combinations: Mechanisms and conditions for optimizing iron mobilization. British Journal of Haematology, 170(6), 874-883. https://doi.org/10.1111/bjh.13512
Aydinok, Y., Kattamis, A., Cappellini, M. D., El-Beshlawy, A., Origa, R., Elalfy, M., Kilinç, Y., Perrotta, S., Karakas, Z., Viprakasit, V., Habr, D., Constantinovici, N., Shen, J., & Porter, J. B. (2015). Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 125(25), 3868-3877. https://doi.org/10.1182/blood-2014-07-586677
Cassinerio, E., Orofino, N., Roghi, A., Duca, L., Poggiali, E., Fraquelli, M., Zanaboni, L., & Cappellini, M. D. (2014). Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients. Blood Cells, Molecules & Diseases, 53(3), 164-167. https://doi.org/10.1016/j.bcmd.2014.04.006
Lal, A., Porter, J., Sweeters, N., Ng, V., Evans, P., Neumayr, L., Kurio, G., Harmatz, P., & Vichinsky, E. (2013). Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules & Diseases, 50(2), 99-104. https://doi.org/10.1016/j.bcmd.2012.10.006
Weiss, H. M., Fresneau, M., Camenisch, G. P., Kretz, O., & Gross, G. (2006). In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metabolism and Disposition, 34(6), 971-975. https://doi.org/10.1124/dmd.105.006429
Lin, C.-H., Chen, X., Wu, C.-C., Wu, K.-H., Song, T.-S., Weng, T.-F., Hsieh, Y.-W., & Peng, C.-T. (2019). Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major-A pilot study. Expert Review of Hematology, 12(4), 265-272. https://doi.org/10.1080/17474086.2019.1593823
Elalfy, M. S., Adly, A. M., Wali, Y., Tony, S., Samir, A., & Elhenawy, Y. I. (2015). Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European Journal of Haematology, 95(5), 411-420. https://doi.org/10.1111/ejh.12507
Gomber, S., Jain, P., Sharma, S., & Narang, M. (2016). Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian Pediatrics, 53(3), 207-210. https://doi.org/10.1007/s13312-016-0821-4
Farmaki, K., Tzoumari, I., & Pappa, C. (2011). Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells, Molecules & Diseases, 47(1), 33-40. https://doi.org/10.1016/j.bcmd.2011.03.007
Totadri, S., Bansal, D., Bhatia, P., Attri, S. V., Trehan, A., & Marwaha, R. K. (2015). The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Pediatric Blood & Cancer, 62(9), 1592-1596. https://doi.org/10.1002/pbc.25533
Divakarjose, R. R., Delhikumar, C. G., & Ram Kumar, G. (2021). Efficacy and safety of combined oral chelation with deferiprone and deferasirox on iron overload in transfusion dependent children with thalassemia - A prospective observational study. Indian Journal of Pediatrics, 88(4), 330-335. https://doi.org/10.1007/s12098-020-03442-5
Alymara, V., Bourantas, D., Chaidos, A., Bouranta, P., Gouva, M., Vassou, A., Tzouvara, E., & Bourantas, K. L. (2004). Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematology Journal, 5(6), 475-479. https://doi.org/10.1038/sj.thj.6200550
Daar, S., & Pathare, A. V. (2006). Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Annals of Hematology, 85(5), 315-319. https://doi.org/10.1007/s00277-005-0075-z
Kattamis, A., Ladis, V., Berdousi, H., Kelekis, N. L., Alexopoulou, E., Papasotiriou, I., Drakaki, K., Kaloumenou, I., Galani, A., & Kattamis, C. (2006). Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial. Blood Cells, Molecules & Diseases, 36(1), 21-25. https://doi.org/10.1016/j.bcmd.2005.11.002
Kolnagou, A., Kleanthous, M., & Kontoghiorghes, G. J. (2010). Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. European Journal of Haematology, 85(5), 430-438. https://doi.org/10.1111/j.1600-0609.2010.01499.x
Mourad, F. H., Hoffbrand, A. V., Sheikh-Taha, M., Koussa, S., Khoriaty, A. I., & Taher, A. (2003). Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. British Journal of Haematology, 121(1), 187-189. https://doi.org/10.1046/j.1365-2141.2003.04240.x
Origa, R., Bina, P., Agus, A., Crobu, G., Defraia, E., Dessì, C., Leoni, G., Muroni, P. P., & Galanello, R. (2005). Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica, 90(10), 1309-1314.
Peng, C.-T., Wu, K.-H., Wu, S.-F., Liang, D.-C., Yang, C.-P., Jang, R.-C., Wang, L.-Y., & Hsiao, C.-C. (2006). Deferiprone or deferoxamine vs. combination therapy in patients with β-thalassemia major: A case study in Taiwan. Hemoglobin, 30, 125-130. https://doi.org/10.1080/03630260500455581
Platis, O., Anagnostopoulos, G., Farmaki, K., Posantzis, M., Gotsis, E., & Tolis, G. (2004). Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatric Endocrinology Reviews, 2(2), 279-281.
Ricchi, P., Ammirabile, M., Spasiano, A., Costantini, S., Cinque, P., Di Matola, T., Pagano, L., & Prossomariti, L. (2010). Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: A retrospective study. European Journal of Haematology, 85(1), 36-42. https://doi.org/10.1111/j.1600-0609.2010.01447.x
Songdej, D., Sirachainan, N., Wongwerawattanakoon, P., Sasanakul, W., Kadegasem, P., Sungkarat, W., & Chuansumrit, A. (2015). Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-Year experience. Acta Haematologica, 133(2), 226-236. https://doi.org/10.1159/000363210
Aydinok, Y., El-Beshlawy, A., Von Orelli-Leber, C., Czarnecki-Tarabishi, C., & Manz, C. Y. (2006). A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major. Blood, 108(11), 557-557. https://doi.org/10.1182/blood.V108.11.557.557
Tanner, M. A., Galanello, R., Dessi, C., Smith, G. C., Westwood, M. A., Agus, A., Pibiri, M., Nair, S. V., Walker, J. M., & Pennell, D. J. (2008). Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance, 10, 12. https://doi.org/10.1186/1532-429X-10-12
Ha, S.-Y., Chik, K.-W., Ling, S.-C., Lee, A. C.- W., Luk, C.-W., Lam, C. W.-K., Ng, I. O.-L., & Chan, G. C.-F. (2006). A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin, 30, 263-274. https://doi.org/10.1080/03630260600642617
El-Beshlawy, A., Manz, C., Naja, M., Eltagui, M., Tarabishi, C., Youssry, I., Sobh, H., Hamdy, M., Sharaf, I., Mostafa, A., Shaker, O., Hoffbrand, A. V., & Taher, A. (2008). Iron chelation in thalassemia: Combined or monotherapy? The Egyptian experience. Annals of Hematology, 87(7), 545-550. https://doi.org/10.1007/s00277-008-0471-2
Voskaridou, E., Komninaka, V., Karavas, A., Terpos, E., Akianidis, V., & Christoulas, D. (2014). Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Transfusion (Paris), 54(3), 646-649. https://doi.org/10.1111/trf.12335
Lal, A., Porter, J., Sweeters, N., Ng, V., Evans, P., Neumayr, L., Kurio, G., Harmatz, P., & Vichinsky, E. (2013). Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules & Diseases, 50(2), 99-104. https://doi.org/10.1016/j.bcmd.2012.10.006
Cassinerio, E., Orofino, N., Roghi, A., Duca, L., Poggiali, E., Fraquelli, M., Zanaboni, L., & Cappellini, M. D. (2014). Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients. Blood Cells, Molecules & Diseases, 53(3), 164-167. https://doi.org/10.1016/j.bcmd.2014.04.006
Porter, J., Taher, A. T., Aydinok, Y., Cappellini, M. D., Kattamis, A., El-Ali, A., Martin, N., & Pennell, D. (2013). Impact of liver iron overload on myocardial T2* response in transfusion-dependent thalassemia major patients treated with deferasirox for up to 3 years. Blood, 122(21), 1016-1016. https://doi.org/10.1182/blood.V122.21.1016.1016
Wood, J. C., Kang, B. P., Thompson, A., Giardina, P., Harmatz, P., Glynos, T., Paley, C., & Coates, T. D. (2010). The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores. Blood, 116(4), 537-543. https://doi.org/10.1182/blood-2009-11-250308
Alavi, S., Sadeghi, E., & Ashenagar, A. (2014). Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload. Blood Research, 49(1), 72. https://doi.org/10.5045/br.2014.49.1.72
Voskaridou, E., Christoulas, D., & Terpos, E. (2011). Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. British Journal of Haematology, 154(5), 654-656. https://doi.org/10.1111/j.1365-2141.2011.08626.x
Origa, R., Cinus, M., Pilia, M. P., Gianesin, B., Zappu, A., Orecchia, V., Clemente, M. G., Pitturru, C., Denotti, A. R., Corongiu, F., Piras, S., & Barella, S. (2022). Safety and efficacy of the new combination iron chelation regimens in patients with transfusion-dependent thalassemia and severe iron overload. Journal of Clinical Medicine, 11(7), 2010. https://doi.org/10.3390/jcm11072010
Aydinok, Y., Nisli, G., Kavakli, K., Coker, C., Kantar, M., & Çetingül, N. (1999). Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematologica, 102(1), 17-21. https://doi.org/10.1159/000040962
Galanello, R., Kattamis, A., Piga, A., Fischer, R., Leoni, G., Ladis, V., Voi, V., Lund, U., & Tricta, F. (2006). A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 91(9), 1241-1243.
Maggio, A., Vitrano, A., Capra, M., Cuccia, L., Gagliardotto, F., Filosa, A., Romeo, M. A., Magnano, C., Caruso, V., Argento, C., Gerardi, C., Campisi, S., Violi, P., Malizia, R., Cianciulli, P., Rizzo, M., D'ascola, D. G., Quota, A., Prossomariti, L., … Gluud, C. (2009). Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: A randomized clinical trial. British Journal of Haematology, 145(2), 245-254. https://doi.org/10.1111/j.1365-2141.2009.07609.x
Jetsrisuparb, A., Komvilaisak, P., Wiangnon, S., & Jetsrisuparb, C. (2010). Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: First evidence of more than 2 years. Journal of Pediatric Hematology/Oncology, 32(5), 400-403. https://doi.org/10.1097/MPH.0b013e3181e015b0
Balocco, M., Carrara, P., Pinto, V., & Forni, G. L. (2010). Daily alternating deferasirox and deferiprone therapy for “hard-to-chelate” β-thalassemia major patients. American Journal of Hematology, 85(6), 460-461. https://doi.org/10.1002/ajh.21711
Pinto, V. M., Balocco, M., Quintino, S., Bacigalupo, L., Gianesin, B., Rizzi, M., Malagò, R., De Franceschi, L., & Forni, G. L. (2018). Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. American Journal of Hematology, 93(10), E338-E340. https://doi.org/10.1002/ajh.25222
Badawy, S. M., Kattamis, A., Ezzat, H., Deschamps, B., Sicard, E., Fradette, C., Zhao, F., Tricta, F., Chung Tsang, Y., Sheth, S., & Piga, A. (2022). The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study. British Journal of Haematology, 197(1), e12-e15. https://doi.org/10.1111/bjh.17999